ASPCF News and Press, Acerus Pharmaceuticals Corp

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) and its subsidiaries were granted creditor protection pursuant to an order (the “ Initial Order ”) g...

TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “ Acerus ”) were granted protection pursuant to an order (the “ Initial Order ”) issued under the Companies ...

TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA,...

TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately. ...

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that it and its wholly-owned subsidiary, Acerus Pharmaceuticals USA, LLC (collectively with the Company, the &...

Acerus Pharmaceuticals press release ( OTCQB:ASPCF ): Q3 GAAP EPS of -$0.54. Revenue of $0.77M (+30.5% Y/Y). Cash as of September 30, 2022 was $3.0 million compared with $2.2 million as of December 31, 2021 For further details see: Acerus Pharmaceuticals GAAP EPS...

TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) --  Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month period ended September 30, 2022. Unless otherwise noted, all...

TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the “ Note ”) in the amount of US$4.91 million ...

Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: A...

Acerus Pharmaceuticals ( OTCQB:ASPCF ) CFO Robert Motz  to resign from the company effective November 20, 2022. The company has begun a process to search for a new CFO and will provide an update at a future date. “I would like to thank Bob f...